Search
tivozanib (Fotivda, AV-951)
Indications:
- metastatic renal cell carcinoma (FDA-approved March 2021)
Dosage:
- 1.5 mg daily, 3 weeks on & 1 week off
Pharmacokinetics:
- long 1/2 life
Adverse effects:
- > 20%
- fatigue, hypertension, diarrhea, anorexia, nausea, dysphonia, hypothyroidism, cough, & stomatitis
- laboratory abnormalities > 5%
- hyponatremia, increased serum lipase, hypophosphatemia [3]
Mechanism of action:
- inhibits VEGF1, VEGF2 & VEGF3
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
antineoplastic tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- Nosov DA el al
Antitumor Activity and Safety of Tivozanib (AV-951) in a
Phase II Randomized Discontinuation Trial in Patients With
Renal Cell Carcinoma
J Clin Oncol. 2012 May 10;30(14):1678-85
PMID: 22493422
http://jco.ascopubs.org/content/30/14/1678
- Journal Watch: Aging/Geriatrics July 2, 2012
ASCO 2012 Report: Genitourinary Cancer
Massachesetts Medical Society
http://oncology-hematology.jwatch.org
- Bankhead C
FDA Approves Tivozanib for Late-Line Renal Cell Carcinoma -
First treatment to improve PFS after two or three prior lines of therapy.
MedPage Today March 11, 2021
https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/91582